Drug interchanges at the pharmacy: safe for cardiovascular disease?

Area of Science:

• Pharmacology
• Pharmaceutical Sciences
• Drug Delivery Systems

Background:

• Sustained-release formulations are increasingly common for managing chronic diseases.
• The concept of drug interchangeability is critical for therapeutic consistency.
• Verapamil serves as a relevant case study due to its widespread use and formulation variations.

Purpose of the Study:

• To explore the implications of sustained-release formulations on drug interchangeability.
• To analyze the specific case of verapamil in the context of interchangeable drug products.
• To address the growing need for clarity on therapeutic equivalence in chronic disease treatment.

Main Methods:

• Literature review on sustained-release drug formulations.
• Analysis of regulatory guidelines concerning drug interchangeability.
• Pharmacokinetic and pharmacodynamic comparison of verapamil formulations (details not provided in abstract).

Main Results:

• The development of advanced drug delivery systems raises complex questions about interchangeability.
• Verapamil highlights the challenges in assessing therapeutic equivalence across different sustained-release products.
• Ensuring interchangeability is vital for patient safety and treatment efficacy in chronic conditions.

Conclusions:

• The pertinence of drug interchangeability is heightened by advancements in sustained-release drug technology.
• Further research and clear guidelines are needed to establish interchangeability criteria for verapamil and similar drugs.
• Understanding interchangeability is essential for effective and safe chronic disease management.